Welcome to our dedicated page for BULLFROG AI HLDGS news (Ticker: BFRG), a resource for investors and traders seeking the latest updates and insights on BULLFROG AI HLDGS stock.
BullFrog AI Holdings, Inc. uses artificial intelligence and machine learning to turn complex biomedical data into actionable insights for drug discovery and development. Company news centers on the bfLEAP® platform, data harmonization through bfPREP™, and bfARENAS™, a scenario-based decision engine for pharmaceutical portfolio strategy, target selection, biomarker strategy and clinical trial design.
Recurring updates also cover commercial feasibility agreements with pharmaceutical customers, research-institution collaborations, white papers and conference participation in life sciences and oncology. Corporate news includes Nasdaq continued-listing compliance, at-the-market and equity-line financing activity, balance-sheet updates, and shareholder communications tied to the company’s common stock and tradable warrants.
BullFrog AI (NASDAQ: BFRG) is hosting a live investor webinar on June 12, 2024, at 4:15 p.m. ET, featuring insights from CSO Tom Chittenden and LIBD CEO Daniel Weinberger on their collaborative research. The study, using over 2,800 brain samples, has revealed novel insights into psychiatric conditions such as schizophrenia and bipolar disorder through advanced AI techniques. This collaboration has enabled clustering based on biological data, uncovering potential biomarkers and drug targets. The event aims to provide comprehensive details on these findings and discuss future revenue opportunities through potential pharmaceutical partnerships.
BullFrog AI and the Lieber Institute for Brain Development (LIBD) announced significant progress in their collaboration to identify novel drug targets for neuropsychiatric disorders. Using AI and machine learning, they have discovered patient subgroups within conditions like major depression, schizophrenia, and bipolar disorder. This approach led to identifying key genes that present new potential drug targets. BullFrog AI is applying Causal AI to validate these targets, aiming to develop targeted treatments for psychiatric disorders. The collaboration has also started engagements with pharmaceutical companies for strategic partnerships.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.